Controlling residual solvent levels in pharmaceutical and nutraceutical products is essential for both product safety and regulatory compliance. Organic solvents used during synthesis, extraction, or purification can remain in the finished product at trace concentrations. Even at low levels, certain solvents pose significant toxicological risks.
At NJ Labs, we provide residual solvents testing by headspace gas chromatography (HS-GC) in accordance with USP <467>, the primary compendial method for residual solvent analysis in drug substances, excipients, and drug products. As an FDA and DEA-registered laboratory, NJ Labs delivers validated, defensible analytical data suitable for regulatory submissions and internal quality control programs.
Our analytical chemistry team performs method-compliant solvent screening, quantification of Class 1, 2, and 3 solvents per the ICH Q3C framework, and method development for non-standard matrices including complex excipients and lipid-based formulations.
Residual solvents are volatile organic chemicals that are either intentionally used or incidentally produced during the manufacture of active pharmaceutical ingredients (APIs), excipients, or drug products. Because they serve no therapeutic function and may present toxicological risks at elevated concentrations, pharmaceutical and nutraceutical products must contain residual solvents at or below levels established by safety data and regulatory limits.
Common manufacturing sources of residual solvents during manufacturing include:
Even trace quantities of certain solvents, particularly Class 1 compounds such as benzene, can pose significant safety risks. Therefore, accurate residual solvent testing is a critical quality control step at both the API and finished product stages.
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guideline Q3C classifies residual solvents into three categories based on their toxicity profiles and potential risk to human health. These classifications are incorporated into USP <467> and are recognized by regulatory agencies worldwide, including the FDA and EMA.
PDE stands for Permitted Daily Exposure. Class 2 limits vary depending on the individual solvent and its route of administration. The limits provided are representative values according to USP <467> / ICH Q3C. For Class 3 Option 1, the limit: 0.5% (5,000 ppm) per solvent when the daily dose is 10g or less.
| Class | ICH Designation | Toxicity Profile | Common Examples | Typical Limit |
|---|---|---|---|---|
| 1 | Solvents to be avoided | Known or suspected human carcinogens; unacceptable environmental hazards | Benzene, carbon tetrachloride, 1,2-dichloroethane, 1,1-dichloroethene | 2 ppm (benzene) |
| 2 | Solvents to be limited | Non-genotoxic animal carcinogens or possible causative agents of irreversible toxicity; limits based on PDE | Acetonitrile (410 ppm), methanol (3,000 ppm), methylene chloride (600 ppm), toluene (890 ppm), hexane (290 ppm) | Per PDE (mg/day) |
| 3 | Solvents with low toxic potential | Low toxic potential to humans; no health-based exposure limit required at levels normally found in pharmaceuticals | Acetic acid, acetone, ethanol, ethyl acetate, isopropyl alcohol, heptane, methyl ethyl ketone | 0.5% (Option 1)
|
Class 1 solvents are associated with unacceptable toxicity or irreversible adverse effects and should be avoided in pharmaceutical manufacturing. If their use cannot be avoided, residual levels must be strictly controlled and justified. Class 2 solvents are not genotoxic but can cause organ toxicity, and their limits are determined based on Permitted Daily Exposure (PDE) values derived from animal studies. Class 3 solvents are considered low risk and are generally regarded as safe when levels are below 0.5%, provided the daily dose does not exceed 10g.
Regulatory agencies in the US, Europe, and other major markets require pharmaceutical manufacturers to ensure that residual solvent levels in finished products meet established safety limits. Without validated analytical data, manufacturers cannot confirm product safety, secure or maintain product approvals, or effectively respond to regulatory inquiries.
Residual solvent testing supports manufacturers by:
NJ Labs conducts residual solvent analysis using headspace gas chromatography (HS-GC), the method specified in USP <467> and the industry standard for volatile organic compound analysis in pharmaceutical matrices.
Headspace analysis is a sample introduction technique in which a sample is sealed in a vial and heated to achieve thermal equilibrium. Volatile compounds partition from the sample matrix into the gas phase (headspace), above the sample. A defined volume of this headspace gas is then transferred directly to the gas chromatograph for separation and detection.
This technique offers several critical advantages for residual solvent analysis:
Following headspace introduction, analytes are separated by the GC column. They are detected using a flame ionization detector (FID), which offers excellent sensitivity and linearity for most residual solvents and is the standard detector for USP <467> analysis. We also offer confirmation with the GC-MS/MS system for specific applications requiring higher sensitivity. However, please note headspace analysis is not applicable to our GC-MS/MS system. The method enables simultaneous detection and quantification of multiple solvents in a single analytical run, including all Class 1 and Class 2 solvents listed in USP <467> and, where applicable, Class 3 solvents.
Many standard residual solvent protocols are designed for simple aqueous or DMSO-soluble matrices. While NJ Labs conducts analysis of certain excipients such as poloxamers and polymers, they are generally covered by their respective monographs and are not used for residual solvent testing under USP <467>.. If your product matrix presents analytical challenges, contact our team to discuss a customized testing approach before sample submission.
USP <467>, previously referred to as the Organic Volatile Impurities (OVI) chapter, defines three analytical procedures for residual solvent testing. The procedure used depends on the solubility characteristics of the sample in water and other standard solvents.
| Procedure | Applicability | Description | Typical Sample Types |
|---|---|---|---|
| Procedure A | Screening for unknown residual solvents | For when residual solvents are unknown, this procedure uses different chromatographic selectivity to confirm the identity of Class 1 or 2 solvents by matching retention times in both Procedures A and B. | APIs, aqueous drug products, water-soluble excipients |
| Procedure B | Screening for unknown residual solvents | For when residual solvents are unknown, this procedure uses different chromatographic selectivity to confirm the identity of Class 1 or 2 solvents by matching retention times in both Procedures A and B. | Non-aqueous drug products, lipid-based formulations, polymers, waxes |
| Procedure C (General Quantitative) | Quantitative testing for known solvents | Used for quantitative analysis when residual solvents are known. This procedure also applies to non-compendial solvents or matrices that do not fit Procedures A or B. | Products with unique solvent profiles; novel solvents not covered under Procedures A or B |
Note: USP <467> was previously titled ‘Organic Volatile Impurities (OVI).’ Both terms refer to the same compendial chapter. NJ Labs also supports non-USP residual solvent testing requirements including EP 5.4 (European Pharmacopoeia equivalent), ICH Q3C-based method development, and custom solvent panels for non-compendial applications.
Residual solvent data is required as part of drug substance and drug product characterization for regulatory submissions in most major markets. APIs, which are typically manufactured through multi-step organic synthesis, are the most common source of Class 1 and Class 2 solvent exposure. Testing is usually required at each synthetic stage as well as in the final isolated material.
Botanical extraction processes commonly use hydrocarbon solvents (hexane, heptane), alcohols (ethanol, isopropyl alcohol), and occasionally halogenated solvents. Solvent residues in botanical extracts and finished dietary supplements are subject to USP <467> requirements or market-specific limits, which may vary based on product claims and regional regulatory standards.
Though USP <467> is primarily a pharmaceutical standard, cosmetic manufacturers use residual solvent testing to comply with EU Cosmetics Regulation requirements, ISO 22716 GMP expectations, or their own internal safety guidelines. Products containing solvent-based extracts, polymer solutions, or fragrance components may contain residual volatile compounds that require characterization.
Residual solvents in polymers, adhesives, and specialty chemicals can affect product performance, off-gassing behavior, and regulatory compliance, especially for materials used in medical devices or food-contact applications.
NJ Labs provides USP <467> residual solvents testing by headspace gas chromatography for pharmaceutical, nutraceutical, cosmetic, and chemical products. Our accredited laboratory offers validated analytical procedures, multi-solvent detection, and detailed regulatory-ready reports.
To initiate a project, it is helpful to have the following information ready: product type and sample matrix, the solvents of concern or the manufacturing solvents used, whether the product is subject to USP <467> or another regulatory standard, and any submission or release timeline.
Contact our analytical chemistry team today. We typically respond to testing inquiries within one business day and can provide a customized project scope and quote. All project discussions are confidential.
USP <467> is a compendial chapter in the United States Pharmacopeia that establishes analytical procedures and acceptance limits for residual solvents in pharmaceutical drug substances, excipients, and drug products. It is based on the ICH Q3C guideline, which classifies solvents into three categories based on their toxicological risk. Previously titled Organic Volatile Impurities (OVI), both terms refer to the same testing standards